Cargando…

Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study

INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA in...

Descripción completa

Detalles Bibliográficos
Autores principales: Gilson, Mélanie, Gossec, Laure, Mariette, Xavier, Gherissi, Dalenda, Guyot, Marie-Hélène, Berthelot, Jean-Marie, Wendling, Daniel, Michelet, Christian, Dellamonica, Pierre, Tubach, Florence, Dougados, Maxime, Salmon, Dominique
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945039/
https://www.ncbi.nlm.nih.gov/pubmed/20637100
http://dx.doi.org/10.1186/ar3087
_version_ 1782187166739202048
author Gilson, Mélanie
Gossec, Laure
Mariette, Xavier
Gherissi, Dalenda
Guyot, Marie-Hélène
Berthelot, Jean-Marie
Wendling, Daniel
Michelet, Christian
Dellamonica, Pierre
Tubach, Florence
Dougados, Maxime
Salmon, Dominique
author_facet Gilson, Mélanie
Gossec, Laure
Mariette, Xavier
Gherissi, Dalenda
Guyot, Marie-Hélène
Berthelot, Jean-Marie
Wendling, Daniel
Michelet, Christian
Dellamonica, Pierre
Tubach, Florence
Dougados, Maxime
Salmon, Dominique
author_sort Gilson, Mélanie
collection PubMed
description INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA infections during TNFα-blocker treatments. Each case was compared to two controls (with TJA and TNFα-blocker therapy, but without TJA infection) matched on age (±15 years), TJA localization, type of rheumatic disorder and disease duration (±15 years). Statistical analyses included univariate and multivariate analyses with conditional logistic regression. RESULTS: In the 20 cases (18 rheumatoid arthritis), TJA infection concerned principally the knee (n = 12, 60%) and the hip (n = 5, 25%). Staphylococcus was the more frequent microorganism involved (n = 15, 75%). Four patients (20%) were hospitalized in an intensive care unit and two died from infection. Eight cases (40%) versus 5 controls (13%) had undergone primary TJA or TJA revision for the joint subsequently infected during the last year (P = 0.03). Of these procedures, 5 cases versus 1 control were performed without withdrawing TNFα-blockers (P = 0.08). In multivariate analysis, predictors of infection were primary TJA or TJA revision for the joint subsequently infected within the last year (odds ratio, OR = 88.3; 95%CI 1.1-7,071.6; P = 0.04) and increased daily steroid intake (OR = 5.0 per 5 mg/d increase; 1.1-21.6; P = 0.03). Case-control comparisons showed similar distribution between TNFα-blockers (P = 0.70). CONCLUSIONS: In patients receiving TNFα-blockers, TJA infection is rare but potentially severe. Important risk factors are primary TJA or TJA revision within the last year, particularly when TNFα-blockers are not interrupted before surgery, and the daily steroid intake.
format Text
id pubmed-2945039
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-29450392010-09-25 Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study Gilson, Mélanie Gossec, Laure Mariette, Xavier Gherissi, Dalenda Guyot, Marie-Hélène Berthelot, Jean-Marie Wendling, Daniel Michelet, Christian Dellamonica, Pierre Tubach, Florence Dougados, Maxime Salmon, Dominique Arthritis Res Ther Research Article INTRODUCTION: The objective of this study was to assess natural microbial agents, history and risk factors for total joint arthroplasty (TJA) infections in patients receiving tumor necrosis factor (TNF)α-blockers, through the French RATIO registry and a case-control study. METHODS: Cases were TJA infections during TNFα-blocker treatments. Each case was compared to two controls (with TJA and TNFα-blocker therapy, but without TJA infection) matched on age (±15 years), TJA localization, type of rheumatic disorder and disease duration (±15 years). Statistical analyses included univariate and multivariate analyses with conditional logistic regression. RESULTS: In the 20 cases (18 rheumatoid arthritis), TJA infection concerned principally the knee (n = 12, 60%) and the hip (n = 5, 25%). Staphylococcus was the more frequent microorganism involved (n = 15, 75%). Four patients (20%) were hospitalized in an intensive care unit and two died from infection. Eight cases (40%) versus 5 controls (13%) had undergone primary TJA or TJA revision for the joint subsequently infected during the last year (P = 0.03). Of these procedures, 5 cases versus 1 control were performed without withdrawing TNFα-blockers (P = 0.08). In multivariate analysis, predictors of infection were primary TJA or TJA revision for the joint subsequently infected within the last year (odds ratio, OR = 88.3; 95%CI 1.1-7,071.6; P = 0.04) and increased daily steroid intake (OR = 5.0 per 5 mg/d increase; 1.1-21.6; P = 0.03). Case-control comparisons showed similar distribution between TNFα-blockers (P = 0.70). CONCLUSIONS: In patients receiving TNFα-blockers, TJA infection is rare but potentially severe. Important risk factors are primary TJA or TJA revision within the last year, particularly when TNFα-blockers are not interrupted before surgery, and the daily steroid intake. BioMed Central 2010 2010-07-16 /pmc/articles/PMC2945039/ /pubmed/20637100 http://dx.doi.org/10.1186/ar3087 Text en Copyright ©2010 Gilson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gilson, Mélanie
Gossec, Laure
Mariette, Xavier
Gherissi, Dalenda
Guyot, Marie-Hélène
Berthelot, Jean-Marie
Wendling, Daniel
Michelet, Christian
Dellamonica, Pierre
Tubach, Florence
Dougados, Maxime
Salmon, Dominique
Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title_full Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title_fullStr Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title_full_unstemmed Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title_short Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
title_sort risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor α-blockers: a case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2945039/
https://www.ncbi.nlm.nih.gov/pubmed/20637100
http://dx.doi.org/10.1186/ar3087
work_keys_str_mv AT gilsonmelanie riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT gosseclaure riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT mariettexavier riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT gherissidalenda riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT guyotmariehelene riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT berthelotjeanmarie riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT wendlingdaniel riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT micheletchristian riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT dellamonicapierre riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT tubachflorence riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT dougadosmaxime riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy
AT salmondominique riskfactorsfortotaljointarthroplastyinfectioninpatientsreceivingtumornecrosisfactorablockersacasecontrolstudy